Drugs / Δ9-tetrahydrocannabinol
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07146945 | Aug 2025 → Feb 2026 overdue | — | Delphian Therapeutics Australia Pty, Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Δ9-tetrahydrocannabinol | “S1-221 is a liquid containing cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC).” NCT07146945 ↗ |
| Known as | THC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07146945 ↗ |
| Route | Oral | “A single dose of THC will be administered to participants orally.” NCT07146945 ↗ |